Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study. Issue 10 (24th August 2021)

• Record Type: Journal Article
• Authors: Shimony, Shai; Yeshurun, Moshe; Wolach, Ofir; Ram, Ron; Rozovski, Uri; Shargian, Liat; Zukerman, Tsila; Amit, Odelia; Bar-On, Yael; Krayem, Baher; Avni, Batya; Peretz, Galit; Raanani, Pia; Pasvolsky, Oren
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 10(2021)
• Page Start: 2475
• Page End: 2481
• Publication Date: 2021-08-24
• Subjects: Acute myeloid leukemia -- FLT3 inhibitors -- post-transplantation maintenance; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1913145
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The role of post allogeneic stem-cell transplantation (AlloSCT) FLT3 inhibition for acute myeloid leukemia in the real-world setting is unclear, especially in the era of widespread pre-transplant use of tyrosine kinase inhibitors (TKIs). In a multicenter nationwide study, we assessed 41 patients who were treated with post-transplant TKIs (sorafenib, n = 23, midostaurin, n = 18). The majority also received TKIs pre-transplant ( n = 32, 79%). After a median follow up of 10 months post-transplant (range 3–53.6), 29 patients (71%) were alive and in complete remission. Similar results were seen in a subgroup analysis of pre-transplant TKI recipients (78%). In Univariate analysis, HCT-CI score < 4 and Type of TKI (sorafenib versus midostaurin) predicted longer overall survival. Seventeen patients (41%) suffered from side effects and seven patients (17%) stopped TKI therapy due to adverse events. Overall, our data suggest that post-transplant use of TKIs is safe and effective in an era of their widespread use prior to AlloSCT.